CarsonAllaria Wealth Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

CarsonAllaria Wealth Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-530	Closed	-$4.75K	–	100
2025 Q2	$4.75K	Hold	530	–	–	﹤0.01%	288
2025 Q1	$3.98K	Hold	530	–	–	﹤0.01%	302
2024 Q4	$3.99K	Hold	530	–	–	﹤0.01%	293
2024 Q3	$4.03K	Buy	530 +300	+130%	+$2.28K	﹤0.01%	315
2024 Q2	$1.42K	Hold	230	–	–	﹤0.01%	337
2024 Q1	$1.17K	Hold	230	–	–	﹤0.01%	362
2023 Q4	$1.38K	Hold	230	–	–	﹤0.01%	320
2023 Q3	$1.63K	Sell	230 -125	-35%	-$898	﹤0.01%	313
2023 Q2	$2.5K	Buy	355 +125	+54%	+$1K	﹤0.01%	303
2023 Q1	$1.92K	Hold	230	–	–	﹤0.01%	303
2022 Q4	$3K	Hold	230	–	–	﹤0.01%	258
2022 Q3	$3K	Hold	230	–	–	﹤0.01%	255
2022 Q2	$2K	Hold	230	–	–	﹤0.01%	276
2022 Q1	$4K	Hold	230	–	–	﹤0.01%	256
2021 Q4	$3K	Buy	+230	New	+$3.04K	﹤0.01%	295

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CarsonAllaria Wealth Management's BCRX Position: Q3 2025 in Review

CarsonAllaria Wealth Management sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2025, closing a stake of 530 shares — an estimated $4.75K sold.

CarsonAllaria Wealth Management first reported a position in BCRX in Q4 2021 and held it in 15 quarters. The position peaked at $4.75K in Q2 2025. 286 funds tracked by Wall St. Rank hold BCRX as of Q3 2025.

CarsonAllaria Wealth Management reported no remaining BioCryst Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
CarsonAllaria Wealth Management sold 530 BioCryst Pharmaceuticals shares in Q3 2025, an estimated $4.75K.
CarsonAllaria Wealth Management first reported a position in BioCryst Pharmaceuticals in Q4 2021 and held it in 15 quarters.
CarsonAllaria Wealth Management's BioCryst Pharmaceuticals position peaked at $4.75K in Q2 2025.
286 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2025.

Based on CarsonAllaria Wealth Management's 13F filing for Q3 2025, filed 28 Oct 2025.